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Background: Muscle invasive bladder cancer (BC) has a mortality rate of 50% in 5 years, despite the aggressive
treatments currently used. The diagnosis of latent tumor cells in histologically normal lymph nodes (LN) may have
prognostic value and may explain the tumoral recurrence in BC.
Methods: Here we evaluated the use of the AE1AE3 cytokeratin marker through immunohistochemical examination of
LNs to diagnose micrometastasis in patients with BC undergoing radical cystectomy (RC) and lymph node dissection.
Sixty-one patients with pN0 diseases who were submitted to RC were studied. Conventional histological evaluation
indicated that these patients did not have lymph node metastasis. Histological sections were reviewed and analyzed
by immunohistochemistry (IHC) using the AE1AE3 antibody in single sections.
Results: The total number of removed LNs was 832, averaging 13.64 LNs per patient. The IHC evaluation revealed that
LN from 2/61 (3.27%) patients had micrometastasis. At the time of the last follow-up, 41% of all patients were in
complete disease remission and 41.1% had died from BC.
Conclusions: Our study shows that histological analysis using hematoxylin eosin (HE) method by experienced
pathologists is sufficient for the diagnosis of LN metastasis and, therefore, there is no indication for routine IHC
evaluation in patients at histopathological pN0 stage.
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Bladder cancer (BC) is an important public health problem
with an increasing incidence rate. It is the fourth most
common cancer tumor in men and the eighth in women,
with an estimated 356,600 new cases diagnosed annually
worldwide [1]. Radical cystectomy (RC) associated with
pelvic lymphadenectomy (LND) is the standard treatment
for invasive BC [2] and the presence of pre-operative
hydronephrosis [3], perineural, and lymphatic and vascular
invasion [4, 5] influence clinical course and prognosis.
Data from the Bladder Cancer Research Consortium
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sequently die [6]. Lymph node (LN) metastasis is one of
the main prognostic factors in BC; however, its presence
cannot be properly detected by the currently available
imaging methods such as computed tomography (CT),
magnetic resonance imaging (MRI), and PET-scan [7].
Additionally, the incidence of LN micrometastasis
(define as metastasis less than 2 mm diameter) and
its relevance are controversial due in part to the paucity of
studies addressing the topic [8, 9].
As its name implies, cytokeratin AE1AE3 is a mixture
of two different clones of anti-cytokeratin monoclonal
antibodies, AE1 and AE3. Both of these individual clones
detect certain high and low molecular weight keratins.
AE1 detects the low molecular weight cytokeratins suchle is distributed under the terms of the Creative Commons Attribution 4.0
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lecular weight cytokeratins 1, 2, 3, 4, 5, and 6, and the
low molecular weight cytokeratins 7 and 8. By combining
these two reagents, a single reagent with a broad spectrum
of reactivity against both high and low molecular weight
cytokeratins is obtained [10]. Due to its broad reactivity,
AE1AE3 has been used as a useful marker of micrometas-
tasis in epithelial tumors [11].
The aim of our study was to use immunohistochemis-
try (IHC) analyses to evaluate the presence of microme-
tastasis and assess its prognostic role in BC pN0 patients
submitted to RC.Methods
In this retrospective study, a total of 63 patients were
selected among the 300 sequentials BC patient records
available at the Medical and Statistical Filing Service of
the AC Camargo Cancer Center. The selected patients
(with their paraffin blocks and slides archived in the
tumor bank) had bladder urothelial tumors and were
treated with RC + lymph node dissection (LND) at our
institution between 1990 and 2009. Conventional histo-
logical evaluation indicated that these patients did not
have lymph node metastasis (pN0). The same pathologist
reviewed all pN0 LN slides.
Patients who underwent neoadjuvant treatment (except
local/topic BCG therapy), with non-urothelial tumor, and
those whose tumor slides and/or paraffin block were not
available for our study, were excluded from the analysis.
There was no pNx case.
The study was approved by our institution internal
Research Ethics Committee.Immunohistochemistry technique
The sections were mounted on positively charged
glass slides and dried for 30 min at 37 °C. The sections
were deparaffinized in xylene and rehydrated via a
series of graded alcohols. The AE1AE3 antibody (DAKO
Corporation-Denmark) was used as the immunohisto-
chemical marker at the 1:50 dilution. All immunohisto-
chemical procedures were performed automatically in the
auto-stainer Link 48, DAKO®, using the Flex Plus visua-
lization system according to the supplier’s specifications.Statistical analysis
The statistical analysis was performed with the Windows
Statistical Package for the Social Sciences (SPSS) software
version 17.0. The distribution of the epidemiological, clini-
cal, and pathological variables was presented in contin-
gency tables; the measurement of quantitative variables
was expressed by averages and standard deviations.Results
Two of the 63 patients were excluded from the analysis
after lymph node metastasis was identified in their slides
after hematoxylin eosin (HE) staining pathological re-
view, measuring 0,5 mm and 3,0 mm. Another two of
the 61 remaining patients had lymph nodal micrometas-
tasis (one positive LN each patient) as revealed by the
IHC analysis (Fig. 1). These 2 patients were ASA 2, had
invasive tumors pT4, the average size of the lesions was
2.55 cm (2,5 and 2.6 cm, respectively), lymphatic and
perineural invasion. Both had muscle invasive tumors in
preview TUR without CIS, died from surgery complica-
tions and the average hospitalization time was 73 days
(10 and 136, respectively).
The total number of removed LNs was 832, averaging
13.64 LNs per patient (total of 61 patients) (Table 1).
The average follow-up time was 48 months. Hydrone-
phrosis was present in 34.5% of the patients; 32.8% of
the patients presented ASA III anesthetic risk. It was ob-
served that nine patients (14,8%) were operated because
of the disease recurrence and 31.1% of the total number
of patients showed disease progression (RC tumor stage
bigger than TUR tumor stage) of Urothelial carcinoma
was present in 95.1% of the cases and carcinoma in situ
(CIS) in 3.3%. Three patients had pT0 disease and 44.2%
of the cases presented pT3-pT4 pathological stages.
Vascular invasion was present in 15.4% of cases, lympha-
tic invasion in 36.5%, and perineural invasion in 23.6%.
Cancer survival rates at 12, 24, 36, 48, and 60 months
were 82.4%, 68%, 61.8%, 50.9%, and 45.2%, respectively.
At the time of the last follow-up, 41% of patients were
in complete BC remission, 3.3% had BC, 13.1% had died
from other causes, 41.1% had died from BC, and 1.6%
was lost to follow up (Table 2).
The two patients with LN were ASA 2 and had pT4
stage disease, showing an average tumor lesion size of
2.55 cm and presented lymphatic and perineural inva-
sion. An evaluation of the impact of micrometastasis on
survival was not possible because both patients who
presented micrometastatic disease died from surgery
complications.
Discussion
Tumor staging and grade decisively influence the treat-
ment and prognosis of invasive BC. [12]. Therefore,
tumor stage must be precisely determined in order to
select the best course of treatment. Radiological LN
evaluations are limited because CT scans and MRI can-
not identify metastases in LNs of normal size or those
minimally enlarged [7]. Pelvic lymph nodes that are
larger than 8 mm and abdominal LNs that are larger
than 10 mm in their longest axis are considered enlarged
by CT or MRI. The sensitivity of these methods for
detecting lymph node metastasis varies from 48 to 87%.
Fig. 1 Photomicrography of the lymph node tissue affected by BC metastasis. a and b: tissue stained by the hematoxylin-eosin method; c and d:
tissue assessed by IHC using the AE1AE3 marker (original magnification = 400X). a/c and b/d are from each patient described
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not necessarily a marker for further neoplastic disease
[13, 14]. Currently, there is no evidence for the routine
use of PET for evaluating LN staging in bladder cancer
[15]. Therefore, clinical sub-staging of BC is a common
problem. It is estimated that around 20–25% of T1-T4
N0M0 patients who are submitted to RC and LND
present lymph nodal metastasis [16, 17], and these rates
have been shown to increase with the progression of
tumor staging [18]. Pelvic LND is the main LN staging
method, and it has been suggested that increased lymph-
adenectomy extension leads to increased chances of cure
[19]. LN identification can be improved by submitting the
same samples in separate vials [16], by identifying specific
solutions [20], and analyzing 3 mm sections [21].
LN micrometastasis is a marker of poor prognosis in
tumors such as breast, lung, esophagus, stomach, uterus,
and melanoma. SERAJ et al. studied 27 BC patients within
Ta-T3N0 clinical stages. The biopsies of the largestTable 1 LN status in samples from 61 BC patients at pN0 stage
Variable Category N (%)
Lymph node metastasis Absent 59 96.73
AE1AE3 +Marker 2 3.27
Total number of LND 832 100%
LND average number 13.64 (2 – 52)
LND number Up to 14 40 65.60
>14 21 34.40tangible removed LNs were evaluated through RT-PCR
for the presence of uroplakin II (UPII) mRNA. A total of
17% of the LNs from pT2N0 patients and 67% from
pT3N0 patients presented lymph nodal micrometastasis
[8]. RETZ et al. found 29% positivity when investigating
the use of mucin 7 (MUC-7) expression in the detection
of micrometastasis in histologically normal LNs [9]. The
expression of cytokeratin 19 (CK19) and uroplakin II
(UPII) were used in the evaluation of micrometastasis in
760 LNs from 40 patients who underwent RC with LND.
Histopathological review detected 29 positive LNs in six
patients; however, CK19 and UPII positive expression in-
dicated the presence of lymph nodal metastasis in 49 LNs
and 98 LNs, respectively. Patients with micrometastasis
detected by these biomarkers showed poorer survival rates
when compared with patients without micrometastasis,
regardless of the presence of histologically positive LNs
[22]. Recently, MARIN-AGUILERIA et al. analyzed the
role of the expression of 5 genes in identifying LN micro-
metastasis using RT-PCR. The combined expression of
two genes (FXYD3 and KRT20) differentiated the positive
LNs from the controls (healthy) with 100% sensitivity and
specificity. These authors showed that the expression of
two genes identified positive LNs in 20.5% of the pN0
patients evaluated histologically [23].
YANG et al. [11] were the first to evaluate the immu-
nohistochemical role of the AE1AE3 antibody in detecting
micrometastasis in LNs in 229 LNs (pN0) from 19 invasive
BC patients submitted to RC. Three sections were
Table 2 Patients and pathological characteristics
Variable N (%)
Follow-up (months) 48 (1–249)
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tissue block. The antibodies used in the IHC evaluation
were CAM 5.2 and AE1AE3. Only one LN was positive
for CAM 5.2. However, this micrometastasis could be
observed through a more thorough analysis in a deeper
section stained by HE. The authors concluded that LN
analysis with HE method is adequate and has a better
cost-benefit ratio compared to IHC for identifying metas-
tasis in the pelvic LNs of BC patients. Conversely, ABE
et al. [24] recently analyzed the role of AE1AE3 in the
diagnosis of micrometastasis in LNs from patients with
upper urinary tract urothelial carcinoma who underwent
nephroureterectomy associated with retroperitoneal LND.
Seven hundred and fourteen LNs from 51 patients were
reviewed with the HE method and analyzed for AE1AE3
reaction. Micrometastasis was identified in 7 patients
(13.7%). No difference in survival was observed between
patients with and without micrometastasis after 45 months
of follow-up. In our study, only 2 patients considered as
pN0 in the conventional histological evaluation showed
lymph nodal micrometastasis. Survival analysis was not
possible since both patients died from surgical complica-
tions during hospitalization. We observed that since 1996,
the number of surgically dissected LNs has increased sub-
stantially, reaching an average of 20 LNs per patient in the
last decade. Despite the dissection of many LNs and con-
sequently, the increased number of LN analyses, none of
them were positive for AE1AE3 in the IHC evaluation.
The finding of epithelial cells in the LNs, whether by
IHC or the biomolecular method, does not necessarily
indicate the occurrence of metastases, and thus, the
morphological evaluation remains necessary. Benign epi-
thelial inclusions represent ectopic foci of embryonic
epithelium in the Müllerian ducts (paramesonephric
ducts) that can be found in the lymph nodes, periton-
eum pelvic, greater omentum, uterine ligaments, tubes,
and ovaries. The exact frequency with which these inclu-
sions are found in the pelvic and peri-aortic LNs is un-
certain, ranging from 1 to 40% in the literature [25]. The
importance of knowing the benign epithelial inclusions
Cuck et al. Applied Cancer Research  (2016) 36:6 Page 5 of 5lies in the fact that they can be easily mistaken as meta-
static foci.
Our data corroborate the results reported by YANG
et al. [11], who concluded that a thorough histological
analysis using the HE method by experienced BC pa-
thologists is sufficient for the diagnosis of lymph nodal
metastasis and, therefore, no indication for routine IHC
evaluation in patients at pN0 stage is indicated. In
addition, we believe that the LN analysis through a
single section is sufficient for the diagnosis of lymph
nodal metastasis. In conclusion, we do not recommend
the indication of routine IHC evaluations of LNs of
surgically treated pN0 BC patients.
Conclusions
Our study shows that histological analysis using hema-
toxylin eosin (HE) method by experienced pathologists is
sufficient for the diagnosis of LN metastasis and, there-
fore, there is no indication for routine IHC evaluation in
patients at histopathological pN0 stage.
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